A5085998323- Monoclonal and Polyclonal Antibodies Research
- Bone and Dental Protein Studies
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Legal Systems and Institutions
- Oral microbiology and periodontitis research
- Cancer Immunotherapy and Biomarkers
- Protease and Inhibitor Mechanisms
- Bone health and treatments
- Cancer Research and Treatments
- Migration, Identity, and Health
- Oral and Maxillofacial Pathology
- European and International Law Studies
- Health, Medicine and Society
- Immune Response and Inflammation
Inserm
2020-2025
Université de Montpellier
2020-2025
Institut de Recherche en Cancérologie de Montpellier
2021-2025
Institute of Justice
2020
Introduction Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that frequently immunogenic. The aspartic protease cathepsin D (cath-D), a tumor cell-associated extracellular protein with protumor and poor marker in TNBC, prime target antibody-based therapy induce NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). This study investigated whether Fc-engineered...
à la diffusion de documents scientifiques niveau recherche, publiés ou non, émanant des établissements d'enseignement et recherche français étrangers, laboratoires publics privés.
Triple-negative breast cancer (TNBC) has poorer outcomes than other cancers (BC), including HER2
ABSTRACT Extracellular matrix (ECM) remodeling by proteases results in the release of protein fragments that promote tumor progression and metastasis. The protease cathepsin D (cath-D), a marker poor prognosis triple-negative breast cancer (TNBC), is aberrantly secreted microenvironment. Using degradomic analyses TAILS, we discovered matricellular SPARC substrate extracellular cath-D. In vitro , cath-D induced limited proteolysis C-terminal Ca 2+ binding domain at acidic pH, leading to...